Welcome to our dedicated page for Novaccess Global SEC filings (Ticker: XSNX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Novaccess Global's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Novaccess Global's regulatory disclosures and financial reporting.
NovAccess Global Inc. reports no revenue and a net loss of $2,657,889 for the year ended September 30, 2024, narrower than its prior-year loss. The biopharmaceutical company is focused on TLR-AD1, a dendritic cell-based immunotherapy for glioblastoma, and related IDH1 biomarker technology, both still in pre-clinical and clinical development stages.
The company has suspended operations due to lack of funds, carries approximately $2.3 million of largely past-due debt, and its auditors have issued a going concern opinion. Management highlights significant dilution risk from convertible debt, preferred stock, options and warrants, and notes it is exploring financing with Vital Science Innovations. As of January 14, 2026, 61,652,385 common shares were outstanding, with a large pool of authorized but unissued shares that could be used for future financings.